drugset
drugset / Trial / NCT06982040

Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy

NCT06982040 ↗

Phase 2 Not yet recruiting 80 enrolled Nanjing Chia-tai Tianqing Pharmaceutical
RandomizedParallel-groupQuadruple-blindTreatment

Summary

NTQ5082 is a small molecule inhibitor of complement factor B (CFB) that inhibits the enzymatic activity of CFB, thereby blocking the alternative pathway of the complement activation cascade. It is being clinically developed for the treatment of primary IgA nephropathy The main objectives of the study were to assess the efficacy and safety of NTQ5082 capsules in the treatment of patients with primary IgA nephropathy.

Timeline

Start
2025-05
Primary completion
2026-09
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject NTQ5082 Small molecule 100 mg —
Subject NTQ5082 Small molecule 200 mg —
Subject NTQ5082 Small molecule 300 mg —

Indications

IgA glomerulonephritis